Back to Results
First PageMeta Content
Health / Low molecular weight heparin / Deep vein thrombosis / Factor X / European Medicines Agency / Committee for Medicinal Products for Human Use / Pharmacovigilance / Safety pharmacology / Thrombosis / Heparins / Hematology / Medicine


European Medicines Agency London, 19 March 2009
Add to Reading List

Document Date: 2013-07-21 04:57:45

Open Document

File Size: 62,68 KB

Share Result on Facebook

City

London / /

/

Facility

Canary Wharf / /

/

IndustryTerm

active site / similar biological medicinal product / reference medicinal product / biological products / art imaging technique / biotechnology-derived proteins / physico-chemical characterisation / originator product / reactive site / reference product / reference products / chemical / risk management systems / medicinal products / similar biological medicinal products / test medicinal product / manufacturing process / /

MedicalCondition

arterial thrombosis / arterial thromboembolism / acute coronary syndromes / Patients developing thrombocytopenia / deep venous thrombosis / thromboembolism / thrombocytopenia / proximal deep vein thrombosis / Heparin-induced thrombocytopenia type II / unstable angina / venous thromboembolism / pulmonary embolism / anaphylactic reactions / thrombosis / Heparin-induced Thrombocytopenia / /

MedicalTreatment

hip and knee surgery / orthopaedic surgery / hip surgery / surgery / /

Organization

European Medicines Agency London / GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING LOW-MOLECULAR-WEIGHT-HEPARINS DRAFT AGREED BY BIOSIMILAR MEDICINAL PRODUCTS WORKING PARTY / COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE / European Union / /

/

Position

EXECUTIVE / representative for the clinical outcome / SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING LOW-MOLECULAR-WEIGHT-HEPARINS EXECUTIVE / /

ProgrammingLanguage

EC / /

Technology

antibodies / biotechnology / /

URL

http /

SocialTag